Decentralized Clinical Trials Market To Reach $37.62 billion by 2033

The report “Decentralized Clinical Trials Market by Type (Interventional, Observational, Expanded Access) , By Therapeutic Application (Oncology, Cardiology, Neurology, Respiratory, and Other)” is expected to reach USD 37.62 billion by 2033, registering a CAGR of 20.00% from 2026 to 2033, according to a new report by Transpire Insight.

DCTs are studies in which the need for the physical presence of patients in hospital-based trials is reduced or eliminated. Some of the digital tools used for conducting DCTs include wearable devices, e-consent, apps, Electronic Patient-Reported Outcomes (ePRO), trial activities at the patient’s home, and telemedicine. The decentralized clinical trials market comprises dedicated staff & infrastructure, research site-partnerships, adequate regulatory frameworks, sponsors, and patients. The major driving factor of the market is reduced dependency on hospital sites, which improved patient participation and diversity. DCTs have become more useful in the case of disabled & elderly people, and the people who need to travel long distances for research.

DCTs could be revolutionized by adopting the most recent breakthroughs in artificial intelligence (AI), computing technology, and remote monitoring. AI-based sensors and wearables improve patient surveillance, which is particularly important for decentralized clinical trials. AI-based solutions help to reduce the sizes and durations of trials. AI-based analysis help to easily satisfy the statistical demands of clinical trials as a result of increasing production of clinical data from AI-driven tools of remote monitoring and electronic patient-reported outcomes.

The Interventional segment is projected to witness the highest CAGR in the Decentralized Clinical Trials Market during the forecast period.

The interventional part of the market led and will continue to outpace the development of the market for decentralized clinical trials. Clinical trials are crucial for the development of medicine as a whole. These trials provide credible scientific evidence of whether new medications are safer or more effective than existing ones. In order for new medications to ensure access to better treatment for patients, this is the evidence used for approval of new medications.

The Oncology segment is projected to witness the highest CAGR in the Decentralized Clinical Trials Market during the forecast period.

The oncology segment leads the market for decentralized clinical trials in 2023. Improved treatments are required for cancer, which is rapidly ascending to the list of the most prioritized healthcare areas. The main domain is where 85% of cancer services are received. It is thus an important task to ensure that the healthcare professionals within the domain are also able to benefit from clinical trials for better accessibility to research.

The North America region is projected to witness the highest CAGR in the Decentralized Clinical Trials Market during the forecast period.

North America the decentralized clinical trials (DCTs) market was dominated by North America in 2023. North America is home to a large presence of healthcare, biotech, and pharmaceutical sectors. These sectors show regular interest in clinical studies to introduce new drugs, therapeutics, and medical devices & equipment, among other things, to enhance healthcare practices. Besides, it is involved in technological developments to enhance growth of an appropriate DCTs market within a shorter span of time.

The U.S. accounted for the largest market share in the decentralized clinical trials (DCTs) market in North America. The FDA recognizes that decentralized clinical trials offer considerable advantage and benefit. The Food and Drug Administration (FDA) in the United States is also adopting additional procedures in May 2023 to make decentralized clinical trials (DCTs) for drugs, biologics, and devices, where operations in part or in whole are conducted outside traditional clinical trial facilities, easier. A new guidance document has been formulated, which advises sponsors, investigators, and others concerned, on how to apply DCTs in encouraging medical product development and research.

Key Players

The top 15 players in the Decentralized Clinical Trials Market include IQVIA, Labcorp, ICON, Covance, CRF Health, Parexel, LEO Innovation Lab, Thermo Fisher, Huma, Oracle, Medidata, PRA Health Sciences, Clinical Ink, Signant Health, Medable, and Science 37.

Drop us an email at:

inquiry@transpireinsight.com

Call us on:

+91 7666513636